Mount Sinai researchers identify genetic predictors of response to selinexor in multiple myeloma

Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data

The phase I/II LINKER-MM1 trial of linvoseltamab in R/R MM produced positive pivotal data in patients with relapsed/refractory multiple myeloma.

April 12, 2024

Vol.50 No.15

Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).

April 05, 2024

Vol.50 No.14

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

Clinical Roundup

RCSI preclinical research identifies promising drug combination for MM treatment

Royal College of Surgeons in Ireland preclinical research found that venetoclax, a medication currently approved for leukemia, may have benefits for patients with multiple myeloma when used in combination with another drug—a demethylase inhibitor called 5-azacytidine. This discovery offers a new avenue of treatment options for the currently incurable disease.

March 29, 2024

Vol.50 No.13